Market Cap
$59.5B
ARGX
ARGENX SE
$915.20 ▼ -2.22%
Prev close $936.00Market cap$59.5B
ConsensusStrong Buy
12-mo target$1,180.17 (+28.5%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (8/10)34 New Institutional Positions16 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ARGX right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (88%)
Inst. Holders
50 funds
Inst. Value
$20.4B
Inst. Activity
34 buys / 16 sells
SEC Reports
11
Press Releases
3
Price chart 30d -13.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 other
Sep 10, 2026 SEC argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
September 29, 2026, 8:00 AM EST
A mixed institutional cluster in ARGX for 2026-Q2 shows 46 buyers accumulating $273.7M net, led by Capital Group ($82.1M
INST-CLUSTER — Impact 5/10
Argenx announced positive topline results from the Phase 3 ALKIVIA trial of VYVGART Hytrulo (efgartigimod) in autoimmune
6-K — Impact 8/10
argenx has commenced a tender offer to acquire all outstanding shares of Forte Biosciences for $77.00 per share in cash,
Impact 7/10
argenx announced a definitive agreement to acquire Forte Biosciences for $77 per share in cash, a total equity value of
6-K — Impact 7/10
argenx is acquiring Forte Biosciences for $77/share in cash, total equity value ~$2.2B, an 86% premium to Forte's VWAP s
Impact 7/10
Jun 30, 2026 Inst.
Pictet Asset Management Holding — ADD
198,282 shares ($183.8M)
Jun 30, 2026 Inst.
1832 Asset Management L.P. — ADD
157,940 shares ($146.5M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
88% rate it Buy or better · 25 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 8, 2026 | Wedbush | REITERATE | Outperform | 57% |
| Sep 3, 2026 | Wedbush | REITERATE | Outperform | 57% |
| Aug 31, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Aug 26, 2026 | UBS | UPGRADE | Buy | 55% |
| Aug 26, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Aug 18, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Aug 18, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Aug 18, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Aug 18, 2026 | Citizens | MAINTAIN | Market Outperform | 38% |
| Aug 18, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 8 | 14 | 3 | 0 | 0 | 88% | |
| Aug 1, 2026 | 8 | 15 | 2 | 0 | 0 | 92% | |
| Jul 1, 2026 | 8 | 15 | 2 | 0 | 0 | 92% | |
| Jun 1, 2026 | 8 | 15 | 2 | 0 | 0 | 92% | |
| May 1, 2026 | 8 | 15 | 2 | 0 | 0 | 92% | |
| Apr 1, 2026 | 8 | 15 | 2 | 0 | 0 | 92% | |
| Mar 1, 2026 | 8 | 14 | 3 | 0 | 0 | 88% | |
| Feb 1, 2026 | 8 | 14 | 3 | 0 | 0 | 88% |
Price targets
Where 23 covering analysts think ARGX trades over the next 12 months.
$1,180.17 +28.5% upside Strong Buy
Current$918.34 Low$900.00 Median$1,173.00 High$1,450.00 23 analysts
$900.00$1,450.00
Analyst rating Buy· 1.5/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
11 SEC filing reports analyzed · 5 bullish, 0 bearish, 1 mixed, 5 neutral · avg impact 5.2/10.Plus 3 press releases.
MIXEDINST-CLUSTER5/10
A mixed institutional cluster in ARGX for 2026-Q2 shows 46 buyers accumulating $273.7M net, led by C
Sep 10, 2026
BULLISH6-K8/10
Argenx announced positive topline results from the Phase 3 ALKIVIA trial of VYVGART Hytrulo (efgarti
Aug 17, 2026
BULLISH6-K7/10
argenx announced a definitive agreement to acquire Forte Biosciences for $77 per share in cash, a to
Jul 27, 2026
NEUTRALPRESS-RELEASE5/10
{ "summary": "argenx reported Q2 2026 diluted EPS of $7.32, beating the $6.13 consensus by 19.4%, wi
Jul 23, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 29, 2026
other
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
September 29, 2026, 8:00 AM EST
Sep 21, 2026
Clinical Trial
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
Phase Phase 3 — COMPLETED
Sep 17, 2026
other
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
September 17, 2026 – 22:01PM CET
Sep 15, 2026
Clinical Trial
A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase Phase 2 — TERMINATED
Sep 9, 2026
ftd
FTD: ARGX — 2,246 shares ($2.3M) failed to deliver
Settlement: 20260909, Price: $1007.07, FTD Value: $2,261,879.22, ARGENX SE SPONSORED ADS (NLD)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-27.83 | $-27.83–$-27.83 | -637.3% | -453.4% | 4↑ 0↓ | $1.6B | 1 |
| Next Q | $8.77 | $8.77–$8.77 | 9.3% | +3.0% | 4↑ 0↓ | $1.8B | 1 |
| Current FY | $18.36 | $-5.36–$28.07 | -6.2% | -32.3% | 5↑ 0↓ | $6.3B | 4 |
| Next FY | $34.72 | $29.57–$40.61 | 89.1% | -11.8% | 8↑ 4↓ | $7.6B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-27.830 | — |
| 7d ago | $-27.830 | — |
| 30d ago | $7.875 | -35.705 |
| 60d ago | $7.363 | -35.193 |
| 90d ago | $6.766 | -34.596 |
Institutional ownership
Which big funds own ARGX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $20.4B total value (22,111,507 shares) as of 2026-Q2. Top holders: FMR, Jupiter, Capital. Net buying activity: 34 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 5,231,452 | $4.9B | 23.8% | — |
| Jupiter Topco LLC | 2,474,015 | $2.3B | 11.2% | — |
| Capital World Investors | 2,199,770 | $2.0B | 10.0% | — |
| Artisan Partners Limited Partnership | 1,508,778 | $1.4B | 6.9% | — |
| Avoro Capital Advisors LLC | 1,000,000 | $927.8M | 4.5% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 930,548 | $863.3M | 4.2% | — |
| BlackRock, Inc. | 777,237 | $721.1M | 3.5% | — |
| RTW INVESTMENTS, LP | 709,446 | $658.2M | 3.2% | — |
| MORGAN STANLEY | 643,123 | $596.7M | 2.9% | — |
| Invesco Ltd. | 443,990 | $411.9M | 2.0% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Pictet Asset Management Holding SA | ADD | 148,306 | 198,282 | +33.7% | $183.8M |
| 1832 Asset Management L.P. | ADD | 84,200 | 157,940 | +87.6% | $146.5M |
| BARCLAYS PLC | DOUBLED | 5,500 | 134,427 | +2344.1% | $124.7M |
| MILLENNIUM MANAGEMENT LLC | ADD | 72,365 | 94,401 | +30.5% | $87.6M |
| Fiera Capital Corp | TRIM | 217,198 | 90,423 | -58.4% | $83.9M |
| Capital Research Global Investors | NEW | — | 88,511 | — | $82.1M |
| Candriam S.C.A. | ADD | 54,148 | 80,120 | +48.0% | $74.3M |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | DOUBLED | 27,506 | 61,312 | +122.9% | $56.9M |
| CANADA PENSION PLAN INVESTMENT BOARD | NEW | — | 60,577 | — | $56.2M |
| Squarepoint Ops LLC | DOUBLED | 18,679 | 58,400 | +212.7% | $54.2M |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ARGX.
Shares short
1,313,174
Settlement Sep 15, 2026
Change vs prior
+4.3%
Semi-monthly cycle
Days to cover
6.3
At avg daily volume
Of shares outstanding
≈2.1%
Estimate — not % of float
All ARGX filing & press-release reports (14)
- INST-CLUSTER reportSep 10, 2026
- 6-K reportAug 17, 2026
- PRESS-RELEASE reportAug 6, 2026
- 6-K reportJul 27, 2026
- PRESS-RELEASE reportJul 27, 2026
- PRESS-RELEASE reportJul 23, 2026
- PRESS-RELEASE reportJul 16, 2026
- 6-K reportJun 23, 2026
- 6-K reportJun 3, 2026
- PRESS-RELEASE reportMay 8, 2026
- 6-K reportMay 6, 2026
- PRESS-RELEASE reportMay 6, 2026
- PRESS-RELEASE reportApr 30, 2026
- 6-K reportApr 20, 2026